ReviewJournal of translational medicine2025
Exploring UBASH3A: from immune regulation to autoimmune diseases.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
UBASH3A, also known as TULA or STS-2, is a lymphoid protein that has recently emerged as a novel regulator of T-cell activation and function. It used to be discussed as a member of the UBASH3/TULA/STS family to study the unique triple domain structure and protein‒protein interactions. In this review, we focus on the multifaceted regulatory roles of UBASH3A in biological processes within T cells. Furthermore, genetic variants in UBASH3A have been linked to at least five autoimmune phenotypes. Therefore, a broader understanding of the regulatory effects of UBASH3A in innate immunity and adaptive immunity could enable further improvements in the treatment of autoimmune disorders, antimicrobial therapy, and cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.